Journal
BMC CANCER
Volume 18, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12885-018-4845-0
Keywords
N-cadherin; Cancer; Metastasis; Haematological malignancies; Therapeutic target
Categories
Funding
- Cancer Australia Priority-driven Collaborative Cancer Research Scheme
- Leukaemia Foundation
- Cancer Council SA Beat Cancer Project
- State Government of South Australia through the Department of Health
Ask authors/readers for more resources
In many types of solid tumours, the aberrant expression of the cell adhesion molecule N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the acquisition of an aggressive tumour phenotype. This transition endows tumour cells with the capacity to escape from the confines of the primary tumour and metastasise to secondary sites. In this review, we will discuss how N-cadherin actively promotes the metastatic behaviour of tumour cells, including its involvement in critical signalling pathways which mediate these events. In addition, we will explore the emerging role of N-cadherin in haematological malignancies, including bone marrow homing and microenvironmental protection to anti-cancer agents. Finally, we will discuss the evidence that N-cadherin may be a viable therapeutic target to inhibit cancer metastasis and increase tumour cell sensitivity to existing anti-cancer therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available